Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chugai
Biotech
Chugai inks $250M deal for Gero’s age-related disease targets
Chugai offered up to $250 million for the chance to develop antibodies against age-related disease targets identified by Gero's AI-driven platform.
Nick Paul Taylor
Jul 7, 2025 3:00am
Roche's Chugai inks Swiss ADC deal potentially worth over $780M
Jan 8, 2025 8:00am
Biofourmis, Chugai team up on measuring endometriosis pain
Jul 22, 2020 11:38am
Verastem pens KRAS-focused drug licensing deal with Chugai
Jan 8, 2020 9:20am
Viela Bio, China's Hansoh pen $220M-plus development deal
May 28, 2019 10:58am
Chugai ponies up $1B+ to combine R&D in Yokohama
May 22, 2019 10:33am
